Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Over the last several years, I've worked with engineering teams building software for life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results